Elizabeth Lawson is an Endocrinology/Metabolic physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Massachusetts General Hospital
55 Fruit Street
Boston, MA 02114
Telephone
617-726-3870Registry record last updated 8 Jul 2007.
Clinical trials
- Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease
Sponsor: Massachusetts General Hospital
- Identifying Oxytocin Deficiency in Adults With Pituitary Disease
Sponsor: Elizabeth Austen Lawson
- Oxytocin Effects on Bone in Children With Autism Spectrum Disorder
Sponsor: Elizabeth Austen Lawson
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABIOMEDProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
62.9%l-Thyroxine41%Levothyroxine Sodium100%Part D<11 patientsSomatostatin Analog11.4%Sandostatin Lar Depot100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
23.8%Corticosteroid23.8%Prednisone100%Part D<11 patientsGenitourinary & hormones
13.3%Androgen13.3%Testosterone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
8 NIH research awards on record, funded 2011–2026 per NIH RePORTER. The latest:
- Neurobiological Underpinnings of Avoidant/Restrictive Food Intake Disorder in Adults
Massachusetts General Hospital
FY2026$846,029R01MH128246 - Oxytocin as a Neuroendocrine Therapy for Obesity in Youth
Massachusetts General Hospital
FY2026$82,500R01DK124223 - Neurobiological Underpinnings of Avoidant/Restrictive Food Intake Disorder in Adults
Massachusetts General Hospital
FY2025$846,029R01MH128246
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”